Check out what we have in store for you in the August Mid-Month Newsletter

HCV Drugs: AbbVie, BMS, Merck

by Alan Franciscus, Editor-in-Chief

In this month’s column of HCV Drugs I discuss the exciting news about the Food and Drug Administration (FDA) approval of AbbVie’s and BMS’s HCV medications, the study results from AbbVie’s once-a-day combination to treat genotype 1b, and the acceptance by the FDA of Merck’s new drug application for grazoprevir and elbasvir and the decision date.

Disablity & Benefits: Balance Billing by Out-of-Network Providers

by Jacques Chambers, CLU

Jacques Chambers monthly column is a MUST READ for anyone who wants to avoid a big surprise on their medical bill. Read this informative article to learn how to avoid costly mistakes that could put you in DEBT.

The Five: HCV Myth Busters

by Alan Franciscus, Editor-in-Chief

The Five column this month tackles some of the most common HCV myths: HCV being a death sentence, which genotype is the worse one, if there are symptoms or not, the myth of a HCV vaccine, and more.

Snapshots

by Alan Franciscus, Editor-in-Chief

The Mid-Month Edition of Snapshots will cover three abstracts—children and HCV treatment, the problem of HCV related cirrhosis medical coding and the numbers, and the association of HCV and cardiac problems.

What’s New! HCSP Events

by Alan Franciscus, Editor-in-Chief

A sneak peak of our new website and the date it will be launched – HINT—September 1, 2105 – check it out!

Click here to read this issue:

Check out what we have in store for you in the August Newsletter

A Brief Overview: Outbreaks of Acute HCV Infections in the U. S.

by Alan Franciscus, Editor-in-Chief

In this review, I will discuss the outbreaks of acute infections of hepatitis C across the United States in urban and rural centers and why the numbers are (again) under reported.

HealthWise: Hepatitis C and Nonalcoholic Fatty Liver Disease

by Lucinda K. Porter, RN

Hepatitis C increases the risk of nonalcoholic fatty liver disease (NAFLD), a metabolic disease that generally occurs in overweight patients. You can do something about NAFLD, and this article suggests how.

Snapshots

by Alan Franciscus, Editor-in-Chief

Read about how treatment with Harvoni improves patient-reported outcomes, how HCV works to escape the immune system and become a chronic infection, and about a new test to tell the difference between acute and chronic infection.

FDA Safety Alert

by Alan Franciscus, Editor-in-Chief

The Food and Drug Administration (FDA) has issued a communication strengthening an existing warning label that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke.

Patients First: HCV and Depression

by Alan Franciscus, Editor-in-Chief

There does seem to be a pretty strong link between HCV and Depression.  Add on to that just having a chronic disease, such as hepatitis C, the difficulty of being approved for the new medications, being a baby boomer—and it is not surprising that many people with hepatitis C are depressed.

What’s New! HCSP Events

by Alan Franciscus, Editor-in-Chief

Check out what’s coming to your neighbourhood soon!

 

Click here to read this issue: